[...]“We are proud to have secured our non-hormonal, non-surgical, easily reversible contraceptive allowing men to participate in the family planning” says Mette Mikkelsen, CEO of VasDeBlock. “This latest patent approval is an important step in our development of long-acting, reversible male contraception!”.
CEO Mette Mikkelsen selected to represent VasDeBlock startup in the LIFE SCIENCE ACADEMY programme co-founded by EU Interreg Öresund-Kattegat-Skagerrak.
[...]“We are pleased to have secured the patent for our non-hormonal, non-surgical, easily reversible contraceptive allowing men to participate in the family planning” said Mette Mikkelsen, CEO of VasDeBlock. “This latest patent approval is an important step in our development of long-acting, reversible male contraception”.
CEO Mette Mikkelsen selected for the WOMEN IN TECH programme.
July, 2020
July, 2020
Selected among ten pitches at NORDIC HEALTHTECH TALENTS demo day 12 April 2019.
Selected for the NORDIC HEALTHTECH TALENTS program
Made it to the finals after an intensive training program
TechSavvy predict to see VasDeBlock in future hospital settings...
Press coverage in the Danish medtech & pharma media
Inventor Niels Lindeburg is interviewed by TV2 Nyhederne (in Danish)
A tube - like vas deferens - can be plugged and later unplugged. That's the idea that electrician Niels Lindeburg came up with
VasDeBlock medical ApS
Storkevaenget 8
DK-4653 Karise
Email: contact@vasdeblock.com
Phone: +45 51372969
VAT: DK-37525758
Copyright (c) 2025 VasDeBlock medical ApS